PolyPeptide Group AG
43.93
CHF
-0.15
(-0.35%)
ISIN
CH1110760852
Return %
Stock
S&P 500
1Y
84.88
14.20
3Y
161.13
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Juan-José Gonzalez
- Full Time Employees
- 1,469
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Neuhofstrasse 24 Baar ZG Switzerland 6340
- IPO Date
- Apr 29, 2021
- Website
- polypeptide.com
- Similar Companies
- Business
- PolyPeptide Group AG operates as a specialized contract development and manufacturing organization (CDMO) focused on peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs) for pharmaceutical and biotech companies worldwide. The company manufactures GMP-grade synthetic peptides from pre-clinical gram quantities through commercial multi-kilogram batches; provides oligonucleotide production for novel therapeutics; offers drug substance synthesis including solid-phase peptide synthesis (SPPS), drug product formulation and filling of injectables, and development services encompassing analytical and regulatory support; supplies generic peptides, cosmetic peptides, and neoantigen peptides for personalized cancer therapies in the United States; and supports therapies targeting metabolic diseases including GLP-1 agonists, cancer, cardiovascular disorders, neurological conditions, and obesity. Founded with roots in 1952 and formally established in 1996 through acquisitions starting with the Peptech facility in Malmö, Sweden, PolyPeptide Group AG maintains its headquarters in Baar, Switzerland, and operates six GMP-certified production sites across Europe (Sweden, France, Belgium), the United States (California), and India. In recent developments, the company advances a €100 million expansion at its Malmö facility using pre-built modules to double SPPS capacity and support a major pharmaceutical partner's metabolic program, with installation completed in 2025 as part of its strategy to double 2023 revenue by 2028; ramps up large-scale SPPS production in Braine-l'Alleud, Belgium, following the 2017 acquisition of Lonza's peptide business and over €100 million invested for a multi-year GLP-1 commercial contract; finalizes debottlenecking in Torrance, California, and progresses doubling of SPPS capacity in Strasbourg, France, slated for late 2025; reports 24% revenue growth in H1 2025 with elevated capital expenditures at 27.6% of revenue; expands its revolving credit facility by €40 million to €151 million in May 2025; and lists shares on the SIX Swiss Exchange under ticker PPGN.SW.
Company News
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India